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Background: Type 2 diabetes differs from type 1 diabetes in its pathogenesis. Type 1 diabetic diaphragm has
altered gene expression which includes lipid and carbohydrate metabolism, ubiquitination and oxidoreductase
activity. The objectives of the present study were to assess respiratory muscle gene expression changes in type 2
diabetes and to determine whether they are greater for the diaphragm than an upper airway muscle.
Methods: Diaphragm and sternohyoid muscle from Zucker diabetic fatty (ZDF) rats were analyzed with Affymetrix
gene expression arrays.
Results: The two muscles had 97 and 102 genes, respectively, with at least ± 1.5-fold significantly changed
expression with diabetes, and these were assigned to gene ontology groups based on over-representation analysis.
Several significantly changed groups were common to both muscles, including lipid metabolism, carbohydrate
metabolism, muscle contraction, ion transport and collagen, although the number of genes and the specific genes
involved differed considerably for the two muscles. In both muscles there was a shift in metabolism gene
expression from carbohydrate metabolism toward lipid metabolism, but the shift was greater and involved more
genes in diabetic diaphragm than diabetic sternohyoid muscle. Groups present in only diaphragm were blood
circulation and oxidoreductase activity. Groups present in only sternohyoid were immune & inflammation and
response to stress & wounding, with complement genes being a prominent component.
Conclusion: Type 2 diabetes-induced gene expression changes in respiratory muscles has both similarities and
differences relative to previous data on type 1 diabetes gene expression. Furthermore, the diabetic alterations in
gene expression differ between diaphragm and sternohyoid.Background
Diabetes mellitus is one of the most rapidly growing
chronic diseases of our time, with human type 2 diabetes
becoming more prevalent than type 1 diabetes due to
factors such as physical inactivity and increased obesity.
Associated with the increasing prevalence of obesity and
type 2 diabetes is the growing problem of obstructive
sleep apnea and its adverse cardiovascular and neuro-
psychiatric consequences. Upper airway respiratory mus-
cles are critical for the maintenance of pharyngeal patency
during wakefulness and sleep, and for the restoration of
pharyngeal patency when obstructive apneas occur during
sleep. Many studies in humans and animal models of* Correspondence: exv4@cwru.edu
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distribution, and reproduction in any mediumdiabetes have confirmed reduced strength and endurance
in respiratory and other skeletal muscles, [1-3] which re-
duces exercise performance and increases dyspnea [4-6].
Interestingly, upper airway muscle contractile properties
are affected less than those of the diaphragm by type 1
diabetes, [3,7] although comparable data in type 2 diabetes
are lacking.
Several cellular mechanisms underlying limb muscle
adverse contractile changes have been identified from
biochemical and electrophysiological studies in animal
models of diabetes [8-11]. With respect to respiratory
muscles, in type 1 diabetic diaphragm the expression of
metabolism genes shifted by a small decrease in lipid
metabolism gene expression and a large increase in
carbohydrate metabolism gene expression; in addition
there was increased expression of protein ubiquitination
genes (a mechanism of protein breakdown), and in-
creased expression of oxidoreductase genes (indicative ofMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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gene expression of the respiratory muscles in the same
manner as type 1 diabetes. Furthermore, it is unknown
whether upper airway muscles are affected by diabetes in a
similar manner as the diaphragm. However it is known
from gene expression studies that compared with the
diaphragm, the sternohyoid muscle has higher expres-
sion of carbohydrate metabolism genes, as well as lower
expression of lipid metabolism genes, especially those
involved directly in fatty acid β oxidation and biosyn-
thesis in the mitochondria [13]. The hypothesis of the
present study is that type 2 diabetes produces substan-
tial changes in gene expression of the upper airway
muscles, which furthermore differs both qualitatively
and quantitatively from those of the diaphragm.
Methods
All studies were approved by the institutional animal
care and use committee and conformed with NIH
guidelines for animal care. Studies were performed on
11 male Zucker Diabetic Fatty (ZDF) rats, an animal
model of obesity and type 2 diabetes, obtained from
Charles River Laboratories (Wilmington, MA). All animals
had free access to food and water. Obese (fa/fa) animals
(n=5) were fed Purina diet #5008, which induces develop-
ment of type 2 diabetes between 8 and 12 weeks of age
(Corsetti et al. 2000). Lean (+/?) littermates (n=6) were fed
normal rodent chow. At an age of eighteen weeks, all
animals were well-anesthetized with a mixture of intrape-
ritoneal ketamine, xylazine and acepromazine following an
all-night fast. Blood obtained from the tail was analyzed
for glucose using a glucometer (Lifescan, Milpitas, CA).
The entire sternohyoid and costal diaphragm muscles
were removed surgically, placed in RNAlater, and stored
at -80°C. At the time of muscle removal, fasting blood
glucose values were 58 ± 7 mg/dl (range 36–77) for the
normal animals, and 183 ± 60 mg/dl (range 133–275) for
the obese ZDF animals (P < 0.001 by unpaired t test). The
obese animals had a final weight that was heavier than the
lean animals (424 ± 28 vs 348 ± 5 grams, for obese and
lean, respectively, P < 0.02). Animals were not treated
with insulin or oral hypoglycemics because the purpose
of the study was to determine the effects of diabetes on
gene expression rather than the extent to which treatment
of diabetes would attenuate the changes.
Gene expression array studies were performed in a
manner similar to that described previously [14-16]. Total
RNA was extracted using Trizol (GibcoBRL, Rockville,
MD), and the RNA pellets were resuspended at 1 μg
RNA/μl DEPC-treated water. This was followed by a
cleanup protocol with a Qiagen (Valencia, CA) RNeasy
Total RNA mini kit. Total RNA was prepared using
Affymetrix (Santa Clara, CA) microarrays, according to
the directions from the manufacturer. Briefly, 8 μg ofRNA was used in a reverse transcription reaction
(SuperScript II; Life Technologies, Rockville, MD) to
generate first strand cDNA. After second strand synthe-
sis, double strand cDNA was used in an in vitro tran-
scription reaction to generate biotinylated cRNA, which
was purified and fragmented. Next, 15 μg of biotin-
labeled cRNA was used in a 300 μl hybridization cock-
tail which included spiked transcript controls. 200 μl
of cocktail was loaded onto Affymetrix RAE 230A
microarrays (Santa Clara, CA) and hybridized for 16 hr
at 45°C with agitation. Standard post-hybridization
washes and double-stain protocols used an Affymetrix
GeneChip Fluidics Station 400. Arrays were scanned
using a Hewlett Packard Gene Array scanner, and ana-
lyzed with Affymetrix GCOS software. The data have
been deposited in NCBIs Gene Expression Omnibus
(GEO, http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=
jjgprsaqewuayxo&acc=GSE21791) and assigned Series acces-
sion number GSE21791.
Statistical analysis was done with Bayesian analysis of
variance for microarrays (BAM), using BAMarray software
(http://www.bamarray.com) [17]. BAM balances the num-
ber of false detections against false non-detections by
means of a special type of inferential regularization (i.e.
borrowing strength across the data). Genes were further
selected as significant based on consistent and appropriate
present and absent calls in all samples per Affymetrix soft-
ware. Subsequently signals were averaged for muscle from
the lean and obese animals, and fold changes were calcu-
lated based on average values from each group. Analysis
focused on genes whose expression changed at least ±1.5
fold in obese compared with lean muscle. To assign bio-
logical meaning to the group of genes with changed ex-
pression, the subset of genes which met the above criteria
was further analyzed with the Gene Ontology (GO) classi-
fication system, using DAVID software (http://david.abcc.
ncifcrf.gov/) [18]. Over-representation of genes with al-
tered expression within specific GO categories was deter-
mined using the one-tailed Fisher exact probability
modified by the addition of a jackknifing procedure, which
penalizes the significance of categories with very few (eg.
one or two) genes and favors more robust categories with
larger numbers of genes [19].
Real-time PCR (RT-PCR) was used to confirm changes
in gene expression as described previously [14-16]. Test-
ing was done using the same tissue that had been used
for gene expression arrays, and was performed on genes
which were chosen from the main, statistically over-
represented, GO groupings based on biological interest.
An Applied Biosystems ABI 7900HT unit with automa-
tion attachment (Foster City, CA) was used for real-time
PCR. This unit is capable of collecting spectral data at
multiple points during a PCR run. To execute the first
step and make archive cDNA, 3 μg of total RNA were
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Biosystems enzymes and reagents in accordance with the
manufacturer’s protocols. RNA samples were accurately
quantitated using a Nanodrop Technologies ND-1000
spectrophotometer (Wilmington, DE). Equal amounts of
total RNA were reverse transcribed and then used in PCR
amplifications. β-Actin had very little variation in ex-
pression across the sample set and therefore was chosen
as the endogenous control. Since many of the target
genes of interest were signaling molecules and likely to
be expressed at low levels, we opted for a low dilution
factor so as to create an environment more conducive
to obtaining reliable results. The cDNA reaction from
above was diluted by a factor of 10. For the PCR step,
9 μl of this diluted cDNA were used for each of three
replicate 15 μl-reactions carried out in a 384 well plate.
Standard PCR conditions were used for the Applied
Biosystems assays: 50°C for 2 min, followed by 95°C for
10 min, followed by 40 cycles of 95°C for 15 sec alter-
nating with 60°C for 1 min each. rtPCR analysis was
similar to our previous studies14-16. Values for RNA
abundance were normalized for each gene with respect
to the endogenous control in that sample (β-Actin),
mean values for fold changes were calculated for each
gene, and statistical testing was performed with the
unpaired t-test (two-tailed).
Results
There were 54 genes with significantly increased expres-
sion and 43 genes with significantly reduced expression in
diabetic compared with normal diaphragm, using the cut-
off of at least a ± 1.5-fold changed expression in addition
to consistent present calls by Affymetrix software and stat-
istical significance by BAM. Using the same criteria, there
were 50 genes with significantly increased expression and
52 genes with significantly reduced expression in diabetic
compared to normal sternohyoid. A complete list of these
genes, including mean fold change values for each gene, is
provided in Additional file 1 (for online publication only).
Classification of genes by Gene Ontology (GO) groups
and statistical testing of over-representation among GO
groups was done separately for each muscle for the genes
with significantly changed expression.
Among the genes with at least 1.5-fold changed expres-
sion in diabetic diaphragm, assignment to GO groups was
possible for 55 using the biological function classification,
61 using the molecular function classification, and 69
using the cellular constituent classification. In the diabetic
sternohyoid, assignment to GO groups was possible for 66
using the biological function classification, 45 using
the molecular function classification, and 58 using the
cellular constituent classification. The GO terms with
over-representation among these genes in the diaphragm
and sternohyoid are indicated in Table 1.The identified GO groups varied considerably with
respect to number of constituent genes (ranging from 2
to 71) and degree of specificity (e.g., from specific terms
such as fatty acid transport and glycerol-3-phosphate
dehydrogenase activity to general terms such as cell and
binding). The more specific GO groups were chosen for
further analysis; in many instances there were clusters
of closely related GO groups that were considered to-
gether (Table 2). Themes common to both muscles were
lipid metabolism, carbohydrate metabolism, muscle
contraction, ion transport and collagen. Themes present
in only diaphragm were blood circulation and oxidore-
ductase activity. Themes present in only sternohyoid
were immune & inflammation and response to stress &
wounding.
The genes in both the diaphragm and sternohyoid
that were classified in either lipid or carbohydrate me-
tabolism GO groups, as well as the direction and magni-
tude of their changed expression, are listed in Table 3.
In the diaphragm there were 9 genes involved in lipid
metabolism (6 increased/3 decreased) and 7 genes in-
volved in carbohydrate metabolism (1 increased/6 de-
creased). In the sternohyoid, there were 10 genes involved
in lipid metabolism (7 increased/3 decreased) and 2 genes
involved in carbohydrate metabolism (0 increased/2
decreased). With respect to specific genes, there were
only 3 genes that had changed expression in both dia-
phragm and sternohyoid in response to diabetes. Carni-
tine O-octanoyltransferase (Crot), which plays a role in
fatty acid transport, was increased in both muscles.
Glycerol-3-phosphate dehydrogenase 2 (Gpd2), a carbohy-
drate metabolism gene which is involved in gluconeogene-
sis, and Acyl-CoA synthetase (Acsl6), a major enzyme in
fatty acid metabolism gene, were decreased in both tissues.
For both muscles together, lipid metabolism gene expres-
sion was increased more than decreased (total 13 vs. 6
genes). On the other hand, for carbohydrate metabolism,
there were more genes that had decreased expression than
those that had increased expression (total 8 vs. 1 genes).
There were 5 muscle contraction genes with signifi-
cantly changed expression in the diaphragm (4 increased/
1 decreased) and 6 with significantly changed expression
in the sternohyoid (4 increased/2 decreased) with diabetes
(Table 3). Of note is that myosin binding protein H
(Mybph) and calsequestrin 2 (Casq2) were increased in
both muscles, while none of the other muscle contraction
genes with changed expression were in common. For both
muscles together muscle contraction gene expression was
increased more than decreased (total 9 vs. 3 genes).
Of the 20 genes from the ion transport GO groups in
the diaphragm with changed expression due to diabetes, 9
are involved in calcium transport (Table 3). Five calcium
genes were increased (Myl6b, Casq2, Itga7, Cacnb2 and
Sln) whereas four of the calcium genes were decreased
Table 1 Statistically significant over-represented Gene Ontology (GO) terms to which genes with changed expression
in diaphragm and sternohyoid of diabetic animals were assigned
DIAPHRAGM
GO classification GO group # genes P value
Biological process
Transport 27 0.000089
Establishment of localization 27 0.00020
Monocarboxylic acid metabolic process 8 0.00035
Localization 29 0.00050
Monosaccharide biosynthetic process 4 0.00067
Alcohol biosynthetic process 4 0.00071
Ion transport 12 0.0015
Alcohol metabolic process 8 0.0018
Hexose metabolic process 6 0.0036
Monosaccharide metabolic process 6 0.0037
Carboxylic acid metabolic process 9 0.0069
Inorganic anion transport 5 0.0072
Organic acid metabolic process 9 0.0073
Regulation of ion transport 3 0.014
Striated muscle contraction 3 0.014
Anion transport 5 0.015
Carbohydrate biosynthetic process 4 0.016
Blood circulation 5 0.016
Circulatory system process 5 0.017
Regulation of biological process 28 0.018
Lipid metabolic process 9 0.019
Heart development 4 0.022
Cardiac muscle development 2 0.027
Cellular carbohydrate metabolic process 6 0.034
Peptide transport 3 0.036
Carbohydrate metabolic process 7 0.040
Circadian rhythm 3 0.040
Multicellular organismal development 18 0.042
Regulation of multicellular organismal process 6 0.044
Developmental process 23 0.045
Regulation of transport 4 0.046
Regulation of the force of heart contraction 2 0.047
Long-chain fatty acid transport 2 0.048
Cellular constituent
Cytoplasm 42 0.0000080
Cytoplasmic part 30 0.0014
Fibrillar collagen 3 0.0015
Sarcoplasmic reticulum 3 0.0047




Plasma membrane 20 0.0072
Endoplasmic reticulum 10 0.0097
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Table 1 Statistically significant over-represented Gene Ontology (GO) terms to which genes with changed expression
in diaphragm and sternohyoid of diabetic animals were assigned (Continued)
Myofibril 4 0.010
Contractile fiber part 4 0.010
Intracellular 52 0.011
Collagen type I 2 0.013
Contractile fiber 4 0.014
Collagen 3 0.018
Smooth endoplasmic reticulum 2 0.032
Cell part 71 0.039
Cell 71 0.039
Molecular function
Protein binding 39 0.0034
Substrate specific channel activity 6 0.018
Calcium ion binding 9 0.024
Structural constituent of bone 2 0.026
Passive transmembrane transporter activity 6 0.030
Transporter activity 13 0.031
Channel activity 6 0.031
Auxiliary transport protein activity 3 0.032
Substrate-specific transporter activity 11 0.033
Oxidoreductase activity 10 0.035
Binding 58 0.039
Transmembrane transporter activity 10 0.044
STERNOHYOID
GO classification GO group # genes P value
Biological process
Regulation of multicellular organismal process 12 0.0000012
Humoral immune response 6 0.0000075
Complement activation 5 0.000014
Activation of plasma proteins during acute inflammatory response 5 0.000016
Acute inflammatory response 6 0.000027
Regulation of immune response 6 0.000027
Regulation of immune system process 6 0.000036
Activation of immune response 5 0.000070
Immune effector process 6 0.000076
Response to stress 17 0.000096
Monocarboxylic acid metabolic process 9 0.00010
Positive regulation of immune response 5 0.00013
Positive regulation of immune system process 5 0.00016
Carboxylic acid metabolic process 12 0.00021
Innate immune response 5 0.00025
Organic acid metabolic process 12 0.00078
Positive regulation of multicellular organismal process 5 0.00091
Long-chain fatty acid transport 3 0.0012
Muscle contraction 6 0.0015
Muscle system process 6 0.0017
Fatty acid transport 3 0.0021
Regulation of muscle contraction 4 0.0022
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Table 1 Statistically significant over-represented Gene Ontology (GO) terms to which genes with changed expression
in diaphragm and sternohyoid of diabetic animals were assigned (Continued)
Response to hormone stimulus 6 0.0028
Fatty acid metabolic process 6 0.0030
B cell mediated immunity 4 0.0032
Immune response 9 0.0033
Anion transport 6 0.0037
Lymphocyte mediated immunity 4 0.0048
Adaptive immune response based on somatic recombination of immune receptors built from
immunoglobulin superfamily domains
4 0.0057
Adaptive immune response 4 0.0062
Humoral immune response mediated by circulating immunoglobulin 3 0.0064
Complement activation-classical pathway 3 0.0064
Defense response 8 0.0067
Leukocyte mediated immunity 4 0.0071
Response to biotic stimulus 6 0.0074
Lipid transport 4 0.0077
Inflammatory response 6 0.0082
Positive regulation of biological process 13 0.0082
Response to external stimulus 10 0.0084
Ion transport 11 0.0089
Inorganic anion transport 5 0.010
Cellular lipid metabolic process 9 0.010
Response to unfolded protein 4 0.011
Response to protein stimulus 4 0.011
Lipid metabolic process 10 0.012
Immune system process 10 0.013
Metabolic process 53 0.015
Response to steroid hormone stimulus 4 0.022
Response to wounding 7 0.023
Response to endogenous stimulus 7 0.028
Response to corticosteroid stimulus 3 0.029
Regulation of Wnt receptor signaling pathway 3 0.030
Response to peptide hormone stimulus 3 0.037
Regulation of biological process 28 0.038
Cellular metabolic process 45 0.049
Cellular constituent
Cytoplasm 45 9.2E-07
Extracellular region part 25 0.000068
Proteinaceous extracellular matrix 9 0.000087
Extracellular matrix 9 0.00010
Extracellular region 25 0.00017
Extracellular space 23 0.00030
Collagen 4 0.0013
Cytoplasmic part 31 0.00140
Fibrillar collagen 3 0.0016
Extracellular matrix part 5 0.00230
Intracellular part 52 0.0040
Endoplasmic reticulum 10 0.0080
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Table 1 Statistically significant over-represented Gene Ontology (GO) terms to which genes with changed expression
in diaphragm and sternohyoid of diabetic animals were assigned (Continued)
Intracellular 54 0.011
Complement component C1 complex 2 0.012
Collagen type I 2 0.012
Glycerol-3-phosphate dehydrogenase complex 2 0.018
Organelle outer membrane 3 0.033
Envelope 7 0.034
Organelle envelope 7 0.036
Molecular function
Glutathione transferase activity 4 0.00076
Catalytic activity 43 0.00090
Calcium ion binding 12 0.0033
Transferase activity- transferring alkyl or aryl (other than methyl) groups 4 0.0042
Glycerol-3-phosphate dehydrogenase activity 2 0.012
Transferase activity 17 0.024
Structural constituent of bone 2 0.029
Magnesium ion binding 5 0.037
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of ion transport genes were sodium and/or potassium
(3 genes), chloride (1 gene), water (1 gene) and zinc (1 gene)
and several other miscellaneous groups. There were
also 4 collagen genes listed in the ion GO groups. Of
the 23 genes from the ion transport GO groups in the
sternohyoid with diabetes-induced changed expression,
10 are involved in calcium transport (Table 3). Half of the
calcium GO group genes increased (Casq2, S100a4, Mgl1,
C1qb and C1qa) while the other half decreased (Fstl1,
Eef2k, Atp2b3, Myl6b and Gpd2). The other smaller
groups of ion transport genes are sodium and/or potas-
sium (3 genes), magnesium (2 genes), and several other
miscellaneous groups. There were also 3 collagen genes
listed in the ion GO group. Among specific genes, three
had altered expression in both muscles: Casq2 was in-
creased and Gpd2 was decreased in both tissues while
Myl6b was increased in diaphragm and decreased in
sternohyoid. Not including the collagen genes, the ion
transport genes were equally divided between increasing
and decreasing expression with diabetes in both muscles
(total 19 vs. 17 genes, not including collagen).
The collagen GO groups in the diaphragm had 3 genes
and the sternohyoid had 4 genes with altered expression
by diabetes. Col1a1 and Col1a2 had changed expression
in both tissues. For both muscles all collagen gene expres-
sion changes were exclusively decreased (total 7 vs. 0).
Two sets of GO groups were over-represented in the
diaphragm but not the sternohyoid muscle (Table 3).
The blood circulation GO groups had 2 genes with in-
creased and 3 genes with decreased expression. The oxi-
doreductase activity GO group had 4 genes with increased
and 6 genes with decreased expression.Two other sets of GO groups were over-represented in
the sternohyoid but not the diaphragm muscle (Table 3).
The immune and inflammatory GO groups had more genes
with increased than decreased expression (total 7 vs 3).
Of note is that all 5 complement genes had increased
expression. The response to stress and wounding GO
groups had 10 genes with increased expression and 7
genes with decreased genes expression. A subset of these
genes were also included in the immune and inflammatory
GO groups, including the 5 complement components with
increased expression. However there were 10 genes in the
stress and wounding GO groups that were not included in
the immune and inflammatory GO groups.
To confirm changes in gene expression in diaphragm
and sternohyoid, high throughput RT-PCR was performed
on a subset of genes. The results which confirmed gene
expression microarray data are presented Table 4. The di-
rection of changes determined by PCR were in the same
direction as that determined by expression arrays. There
was a good and statistically significant correlation between
the magnitude of altered expression measured by gene
expression array and that measured by RT-PCR for these
genes (Figure 1).
Discussion
Lipid and carbohydrate metabolism
The pattern of carbohydrate and lipid substrate use is
regulated closely to meet the metabolic demands of
muscles at rest and during exercise and furthermore
plays important modulatory roles in the pathophysiology
of disease states such as diabetes. There is extensive bio-
chemical literature indicating that diabetes results in a
shift in cellular energetics away from carbohydrate and
Table 2 Specific Gene Ontology groups which were examined in more detail to which genes with changed expression
in diaphragm and sternohyoid of diabetic animals were assigned
GO group category & specific GO term Diaphragm # genes P value Sternohyoid # genes P value
Metbolism - Lipid
Lipid metabolic process 9 0.019 10 0.012
Long-chain fatty acid transport 2 0.048 3 0.0012
Cellular lipid metabolic process 9 0.010
Fatty acid metabolic process 6 0.0030
Lipid transport 4 0.0077
Fatty acid transport 3 0.0021
Metabolism - Carbohydrate
Carbohydrate metabolic process 7 0.040
Monosaccharide metabolic process 6 0.0037
Hexose metabolic process 6 0.0036
Cellular carbohydrate metabolic process 6 0.034
Carbohydrate biosynthetic process 4 0.016
Glycerol-3-phosphate dehydrogenase complex 2 0.018




Contractile fiber part 4 0.010
Contractile fiber 4 0.014
Striated muscle contraction 3 0.014
Muscle system process 6 0.0017
Muscle contraction 6 0.0015
Regulation of muscle contraction 4 0.0022
Ion transport
Ion transport 12 0.0015 11 0.0089
Calcium ion binding 9 0.024 12 0.0033
Inorganic anion transport 5 0.0072 5 0.010
Anion transport 5 0.015 6 0.0037
Regulation of ion transport 3 0.014
Channel activity 6 0.031
Magnesium ion binding 5 0.037
Collagen
Fibrillar collagen 3 0.0015 3 0.0016
Collagen 3 0.018 4 0.0012
Collagen type I 2 0.013 2 0.012
Blood circulation
Blood circulation 5 0.016
Circulatory system process 5 0.017
Oxidoreductase activity
Oxidoreductase activity 10 0.035
Immune & inflammatory
Immune system process 10 0.013
Immune response 9 0.0033
Defense response 8 0.0067
Immune effector process 6 0.000076
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Table 2 Specific Gene Ontology groups which were examined in more detail to which genes with changed expression
in diaphragm and sternohyoid of diabetic animals were assigned (Continued)
Acute inflammatory response 6 0.000027
Regulation of immune system process 6 0.000036
Inflammatory response 6 0.0082
Humoral immune response 6 7.5E-06
Regulation of immune response 6 0.000027
Activation of immune response 5 0.000070
Positive regulation of immune system process 5 0.00016
Complement activation 5 0.000014
Positive regulation of immune response 5 0.00013
Innate immune response 5 0.00025
Adaptive immune response 4 0.0062
Leukocyte mediated immunity 4 0.0071
Lymphocyte mediated immunity 4 0.0048
Adaptive immune response 4 0.0057
B cell mediated immunity 4 0.0032
Humoral immune response immunoglobulin 3 0.0064
Complement activation-classical pathway 3 0.0064
Complement component C1 complex 2 0.012
Response to stress & wounding
Response to stress 17 0.000096
Response to wounding 7 0.023
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uptake and phosphorylation of glucose, phosphorylation
of fructose-6-phosphate, glycoysis, oxidation of pyruvate
and acetate, uptake of acetoacete, production of glycogen,
the proportion of the active complex of pyruvate de-
hydrogenase, and activites of hexokinase, phosphorylase
and phosphofructokinase [20-27]. In addition, diabetic
diaphragm has increased fat metabolism, uptake and
oxidation of free fatty acids, output of glycerol, capacity
for mobilization of intracellular lipids and intracellular
concentrations of triglycerides, free fatty acid and long-
chain fatty acyl-CoA [27-30]. In type I diabetic rat heart
glucose uptake and oxidation decreases, while fatty acid
metabolism increases, indicating that diabetes shifts the
pattern of cardiac energy metabolism in the same direc-
tion as the diaphragm [29,31]. Gerber et al. [32] has previ-
ously found that long chain fatty acids are the major
energy source in streptozotocin-induced type I diabetic
cardiac muscle with their beta-oxidation in mitochondria
generating nearly 70% of the ATP. The gene expression
changes which contribute to the carbohydrate to lipid
metabolic shift have only been partially elucidated. In
streptozotocin-induced diabetic rat diaphragm (a type 1
diabetes model), we found a small increase in expression
of genes involved in lipid metabolism and a large decrease
in expression of genes involved in carbohydrate metabo-
lism, indicating that the gene expression contribution tothe carbohydrate to lipid metabolic shift is directed most
strongly at changes in carbohydrate metabolism [12] In
contrast, type 1 diabetic rat heart has no significant
change in carbohydrate gene expression but substantially
augmented gene expression related to lipid metabolism
[14]. The findings of the present study indicate that in
diaphragm and sternohyoid muscles type 2 diabetes pro-
duces a similar overall shift favoring carbohydrate over
lipid metabolism gene expression that was seen in type 1
diabetic rat diaphragm. However, data from the current
and previous studies indicate that there are considerable
differences between type 1 and type 2 diabetes (Tables 5
and 6), as well as between diaphragm and sternohyoid, in
the number of genes with changed expression, the magni-
tude of the expression changes, and in the identity of the
specific genes involved.
In the present study there were two metabolism genes
with decreased expression in both the diaphragm and
sternohyoid. The first gene was acyl-CoA synthetase long-
chain family member 6 (Acsl6) which catalyzes the ligation
of long chain fatty acids with coenzyme A to produce long
chain acyl-CoAs (Figure 2). This gene also had decreased
expression in streptozotocin-induced diabetic diaphragm
[12] and heart [33]. Acetyl-CoA is converted to malonyl-
CoA which in turn inhibits CTP1 and the transport of
fatty acid into the cell [34]. The second metabolism gene
with decreased expression in both muscles was thyroid
Table 3 Genes with changed expression in diabetic diaphragm and sternohyoid that were assigned to specific
statistically over-represented Gene Ontology (GO) terms
DIAPHRAGM
Gene title Gene symbol FC
Lipid metabolism
Protein kinase, AMP-activated, alpha 1 catalytic subunit Prkaa1 2.2
Cell death-inducing DNA fragmentation factor Cidea 2.2
Diazepam binding inhibitor Dbi 1.7
Carnitine O-octanoyltransferase Crot 1.6
Adipose differentiation related protein Adfp 1.6
Low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor) Lrp1 1.5
Acyl-CoA synthetase long-chain family member 6 Acsl6 −1.7
Thyroid hormone responsive Thrsp −2.1
Transmembrane 7 superfamily member 2 Tm7sf2 −2.5
Carbohydrate metabolism
Protein kinase, AMP-activated, alpha 1 catalytic subunit Prkaa1 2.2
UDP-glucose pyrophosphorylase 2 Ugp2 −1.5
Solute carrier family 2 (facilitated glucose transporter), member 4 Slc2a4 −1.5
Coenzyme Q7 homolog, ubiquinone (yeast) Coq7 −1.6
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 Pfkfb1 −1.7
Glycerol-3-phosphate dehydrogenase 2, mitochondrial Gpd2 −1.7
Dicarbonyl L-xylulose reductase Dcxr −2.0
Muscle contraction
Cysteine and glycine-rich protein 3 Csrp3 4.2
Myosin binding protein H Mybph 3.0
PDZ and LIM domain 3 Pdlim3 1.6
Calsequestrin 2 (cardiac muscle) Casq2 1.5
Myosin, heavy chain 4, skeletal muscle Myh4 −3.6
Ion transport
Calcium channel
Myosin, light chain 6B, alkali, smooth muscle and non-muscle Myl6b 6.8
Calcium channel, voltage-dependent, beta 2 subunit Cacnb2 1.6
Sarcolipin Sln 1.6
Calsequestrin 2 (cardiac muscle) Casq2 1.5
Integrin alpha 7 Itga7 1.5
Glycerol-3-phosphate dehydrogenase 2, mitochondrial Gpd2 −1.7




Sodium channel, voltage-gated, type III, beta Scn3b 2.2
Potassium large conductance calcium-activated channel subfamily M, alpha member 1 Kcnma1 1.5
FXYD domain-containing ion transport regulator 7 Fxyd7 −1.7
Other channels
Low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor) Lrp1 1.5
Solute carrier family 30 (zinc transporter), member 4 Slc30a4 1.5
Aquaporin 1 Aqp1 −1.5
Chloride channel 4-2 Clcn4-2 −1.8
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Table 3 Genes with changed expression in diabetic diaphragm and sternohyoid that were assigned to specific
statistically over-represented Gene Ontology (GO) terms (Continued)
Collagen
Collagen, type I, alpha 2 Col1a2 −1.6
Collagen, type III, alpha 1 Col3a1 −1.7
Collagen, type I, alpha 1 Col1a1 −2.0
Ficolin (collagen/fibrinogen domain containing) 1 Fcn1 −2.1
Collagen
Collagen, type I, alpha 2 Col1a2 −1.6
Collagen, type III, alpha 1 Col3a1 −1.7
Collagen, type I, alpha 1 Col1a1 −2.0
Blood circulation
Cysteine and glycine-rich protein 3 Csrp3 4.2
Potassium large conductance calcium-activated channel subfamily M, alpha member 1 Kcnma1 1.5




2,4-dienoyl CoA reductase 1, mitochondrial Decr1 2.0
IMP (inosine monophosphate) dehydrogenase 2 Impdh2 1.6
Potassium large conductance calcium-activated channel subfamily M, alpha member 1 Kcnma1 1.5
Solute carrier family 30 (zinc transporter), member 4 Slc30a4 1.5
Coenzyme Q7 homolog, ubiquinone (yeast) Coq7 −1.6
Glycerol-3-phosphate dehydrogenase 2, mitochondrial Gpd2 −1.7
S100 calcium binding protein A3 S100a3 −1.7
Dicarbonyl L-xylulose reductase Dcxr −2.0
Phytanoyl-CoA dioxygenase domain containing 1 Phyhd1 −2.1
Transmembrane 7 superfamily member 2 Tm7sf2 −2.5
STERNOHYOID
Gene title Gene Symbol FC
Lipid metabolism
Acyl-CoA thioesterase 2 Acot2 2.4
Nudix (nucleoside diphosphate linked moiety X)-type motif 4 Nudt4 2.1
Retinol saturase (all trans retinol 13,14 reductase) Retsat 1.9
Carnitine palmitoyltransferase 1b, muscle Cpt1b 1.7
Carnitine O-octanoyltransferase Crot 1.6
Carnitine palmitoyltransferase 2 Cpt2 1.5
Solute carrier family 27 (fatty acid transporter), member 1 Slc27a1 1.5
Acyl-CoA synthetase long-chain family member 6 Acsl6 −1.6
Thyroid hormone responsive Thrsp −2.1
Sterol regulatory element binding transcription factor 1 Srebf1 −2.4
Carbohydrate metabolism
Glycerol-3-phosphate dehydrogenase 1 (soluble) Gpd1 −1.6
Glycerol-3-phosphate dehydrogenase 2, mitochondrial Gpd2 −1.8
Muscle contraction
Myosin binding protein H Mybph 8.6
Complement component 4a C4a 2.0
Calsequestrin 2 (cardiac muscle) Casq2 2.0
Cholinergic receptor, nicotinic, delta Chrnd 1.9
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Table 3 Genes with changed expression in diabetic diaphragm and sternohyoid that were assigned to specific
statistically over-represented Gene Ontology (GO) terms (Continued)
Heat shock protein, alpha-crystallin-related, B6 Hspb6 −1.6
Guanidinoacetate N-methyltransferase Gamt −1.6
Ion transport
Calcium channel
S100 calcium-binding protein A4 S100a4 1.9
Complement component 1, q subcomponent, beta polypeptide C1qb 1.7
Complement component 1, q subcomponent, alpha polypeptide C1qa 1.6
Macrophage galactose N-acetyl-galactosamine specific lectin 1 Mgl1 1.5
Calsequestrin 2 (cardiac muscle) Casq2 1.5
Follistatin-like 1 Fstl1 −1.5
Glycerol-3-phosphate dehydrogenase 2, mitochondrial Gpd2 −1.7
Eukaryotic elongation factor-2 kinase Eef2k −2.0
ATPase, Ca++ transporting, plasma membrane 3, (AKA PMCA2) Atp2b3 −2.1
Myosin, light chain 6B, alkali, smooth muscle and non-muscle Myl6b −2.5
Sodium/Potassium channels
FXYD domain-containing ion transport regulator 2 Fxyd2 1.6
Potassium large conductance calcium-activated channel subfamily M, alpha member 1 Kcnma1 1.5
ATPase, Na+/K+ transporting, beta 2 polypeptide Atp1b2 −1.6
Magnesium
Inositol (myo)-1(or 4)-monophosphatase 2 Impa2 1.8
Acyl-CoA synthetase long-chain family member 6 Acsl6 −1.6
Other channels
Latent transforming growth factor beta binding protein 1 Ltbp1 2.0
Cholinergic receptor, nicotinic, delta Chrnd 1.9
2,4-dienoyl CoA reductase 2, peroxisomal Decr2 /// Rab11fip3 −1.6
Solute carrier family 16, member 3 (monocarboxylic acid transporter 4) Slc16a3 −1.7
Amylase, alpha 1A (salivary) Amy1a −1.7
Collagen
Collagen, type V, alpha 1 Col5a1 −1.8
Collagen, type I, alpha 1 Col1a1 −1.9
Collagen, type I, alpha 2 Col1a2 −2.2
Collagen
Collagen, type V, alpha 1 Col5a1 −1.8
Collagen, type XV, alpha 1 Col15a1 −1.9
Collagen, type I, alpha 1 Col1a1 −1.9
Collagen, type I, alpha 2 Col1a2 −2.2
Immune & inflammatory
Cyclin-dependent kinase inhibitor 1A (p21, Cip1) Cdkn1a 2.4
Fc fragment of IgG, low affinity IIb, receptor (CD32) Fcgr2b 2.2
Complement component 4a C4a 2.0
Adipsin Adn 1.8
Complement component 1, q subcomponent, beta polypeptide C1qb 1.7
Complement component 1, q subcomponent, alpha polypeptide C1qa 1.6
Complement factor H Cfh 1.6
Dipeptidylpeptidase 4 Dpp4 −1.9
Myxovirus (influenza virus) resistance 1 Mx1 −1.9
Spondin 2, extracellular matrix protein Spon2 −2.0
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Table 3 Genes with changed expression in diabetic diaphragm and sternohyoid that were assigned to specific
statistically over-represented Gene Ontology (GO) terms (Continued)
Response to stress & wounding
Cyclin-dependent kinase inhibitor 1A (p21, Cip1) Cdkn1a 2.4
Acyl-CoA thioesterase 2 Acot2 2.4
Fc fragment of IgG, low affinity IIb, receptor (CD32) Fcgr2b 2.2
Complement component 4a C4a 2.0
Deleted in malignant brain tumors 1 Dmbt1 1.9
Complement factor D (adipsin) Adn 1.8
Complement component 1, q subcomponent, beta polypeptide C1qb 1.7
Potassium large conductance calcium-activated channel subfamily M, alpha member 1 Kcnma1 1.6
Complement component 1, q subcomponent, alpha polypeptide C1qa 1.6
Complement factor H Cfh 1.6
Epidermal growth factor receptor Egfr −1.5
SRY (sex determining region Y)-box 4 Sox4 −1.6
Serine (or cysteine) peptidase inhibitor, clade H, member 1 Serpinh1 −1.6
Heat shock protein, alpha-crystallin-related, B6 Hspb6 −1.6
Collagen, type I, alpha 1 Col1a1 −1.9
Heat shock protein 2 Hspa2 −2.0
Sterol regulatory element binding transcription factor 1 Srebf1 −2.4
Fold changes (FC) in gene expression are represented in the last column.
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involved in lipogenesis [35,36]. The diaphragm had
decreased expression of transmembrane 7 superfamily
member 2 (Tm7sf2) which is involved in cholesterol
biosynthesis, [37] while the sternohyoid had a decrease
in sterol regulatory element binding transcription factor 1
(Srebf1) which regulates the transcription of genes im-
portant for sterol biosynthesis. Srebf1 also had decreased
expression in limb muscle of 12-week old type 2 diabetic
rat [11].
There were several genes with increased expression
in the lipid metabolism GO group that increased in
previous studies of diabetes. 2,4-dienoyl CoA reductase
1 (Decr1) catalyzes the conversion of 2,4 dienoyl-CoA
to cis-Δ3-enoyl-CoA and is involved in the mitochondrial
long-chain fatty acid beta-oxidation pathway (Figure 2).
In previous studies, Decr1 increased 5-fold in type 1
streptozotocin diabetic rat liver mitochondia [38], 2-fold
in our previous studies in type 1 diabetic rat diaphragm
[12] and heart [14], 2-fold in type 1 diabetic rat heart
[39] and nearly four-fold in limb skeletal muscle of
12 week old type 2 diabetic rats [11]. Adipose differen-
tiation related protein (Adfp) has increased expression
in db/db mouse kidney [40]. Cell death-inducing DNA
fragmentation factor (Cidea), also increased in the dia-
betic diaphragm, may play a role in lipolysis, but its
role is still not clearly defined. In previous studies
Cidea-null mutants have been diabetes-resistant [41,42].
It is possible that Cidea functions by modulating fatty
acid metabolism since the Cidea-null mutants hadmuch lower concentrations of plasma FFA and triglyc-
erides [42].
In the sternohyoid, four out of the six lipid metabolism
genes with increased expression (Cpt1b, Cpt2, Acot2 and
Slc27a1) are also involved directly in fatty acid trans-
port and oxidation. Carnitine palmitoyltransferase (Cpt1b)
catalyses the transfer of long chain fatty acids to carnitine
for translocation across the mitochondrial inner mem-
brane and then Cpt2 is an inner mitochondrial membrane
protein that converts long chain acylcarnitine to long
chain acyl-CoA (Figure 2). They are also increased in
streptozotocin-induced diabetic rat heart [32]. Cpt1b has
heterogeneous changes, depending on tissue type. Cpt1b
expression is increased in human type 2 diabetic adipose
tissue [43] and type 1 diabetic rat heart [39]. However, it is
reduced in human type II vastus lateralis [43] and
streptozotocin-induced diabetic rat liver [44]. Acyl-CoA
thioesterase 2 (Acot 2 or Mte1), catalyzes the hydrolysis of
fatty acyl-CoA molecules into nonesterified fatty acid an-
ions and free CoA in the mitochondria and has increased
expression in heart and soleus of streptozotocin-induced
diabetic rats [45]. Slc27a1 is a fatty acid transporter,
which increases fatty acid supply when its expression is
increased, and therefore is thought to increase fatty acid
metabolism [46].
There were only two genes that had significantly de-
creased expression levels in the sternohyoid carbohydrate
metabolism GO group (Gpd1 and Gpd2). Gpd2 expres-
sion was also decreased in diaphragm muscle. Gpd1 and
Gpd2 are glycerol-3-phosphate dehydrogenase genes that
Table 4 Confirmatory results for changes in gene











Csrp3 4.2 7.6 0.022
Mybph 3.0 4.6 0.0010
Decr1 2.0 3.9 <0.001
Sln 1.6 3.3 0.037
Dbi 1.7 2.6 0.013
Adfp 1.6 2.1 <0.001
Kcnma1 1.5 2.1 <0.001
Crot 1.6 2.0 <0.001
Lrp1 1.5 1.9 0.004
Prkaa1 2.2 1.8 <0.001
Gpd2 −1.7 −1.2 0.010
Acsl6 −1.7 −1.4 0.0060
Pln −2.4 −1.9 0.017
Apln −2.2 −2.2 <0.001










Decr1 3.3 4.7 <0.001
Cdkn1a 2.4 3.7 0.0090
Acot2 2.4 3.3 0.0060
Fcgr2b 2.2 4.0 <0.001
C4a 2.0 2.4 <0.001
Adn 1.8 2.5 0.0060
Cpt1b 1.7 2.2 0.0050
Kcnma1 1.6 1.9 0.0030
Crot 1.6 2.9 0.0020
C1qa 1.6 2.0 0.038
Cfh 1.6 1.7 0.0010
Cpt2 1.5 2.1 0.0040
Slc27a1 1.5 2.1 0.023
Acsl6 −1.6 −1.4 0.0020
Fold changes (FC) in gene expression are represented in the last column.
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which are involved in the interconversion of glycerol-
3-phosphate and dihydroxyacetone phosphate with
concomitant reduction of FAD. Gpd2 also had de-
creased expression in the streptozotocin-induced dia-
betic rat heart [14] and diaphragm [12].
In addition to Gpd2, there were five other genes with
decreased expression in the diaphragm that are involved
in carbohydrate metabolism (Slc2a4, Ugp2, Dcxr, Pfkfb1,
Coq7). Slc2a4, Glucose Transporter 4, is involved in
transporting glucose across the membrane [47] and hasdiminished expression and function in type II diabetic
rat heart [48] and slow muscle fibers and omental fat
of type II diabetic patients [49,50]. Ugp2, UDP-glucose
pyrophosphorylase 2 is essential for sucrose and poly-
saccharide synthesis [51] and has decreased expression
in limb muscle of 12-week old type 2 diabetic rats [11].
The remaining 3 decreased diaphragm carbohydrate
metabolism genes, Dcxr, Pfkfb1 and Coq7, were not
significantly changed in any previous diabetes studies.
Dicarbonyl L-xylulose reductase (Dcxr) functions in
the metabolism of glucose [52]. 6-phosphofructo-2-
kinase (Pfkfb1) is a rate limiting enzyme of glycolysis
[53-57] which catalyzes the synthesis and degradation
of fructose 2,6-bisphosphate. Coq7, coenzyme Q7, is a
component of the electron transport chain which ge-
nerates energy in the form of ATP.
Muscle contraction
There has been a paucity of muscle contraction genes
found to be altered due to diabetes in previous gene
array studies. We are not aware of any muscle genes that
were changed in the sternohyoid that have been found
to be changed previously. However, the expression of
cysteine and glycine-rich protein (Csrp3) gene increased
in calf muscle in streptozotocin-induced diabetic mice,
[58] similar to the diaphragm present study. This gene is
thought to play a role in myogenesis. Mybph and Casq2
were the 2 genes that were increased in both muscles in
the present study. Mybph is a skeletal muscle binding
protein which binds myosin and is probably involved in
the interaction with thick myofilaments in the A-band.
Casq2 is a calcium binding protein that stores calcium
for muscle contraction.
Ion channels and transport
In our previous two studies of streptozotocin-induced type
I diabetic heart and diaphragm gene expression we found
decreased expression in 13 calcium binding genes in heart
[14] and 10 calcium ion genes in the diaphragm [12].
Similar to the diabetic diaphragm in the present study,
there was decreased expression of parvalbumin (Pvalb)
in the nerve, [59] gastrocnemius [8] and diaphragm [12]
of streptozotocin-induced type I diabetic rats. This pro-
tein binds two calcium ions and is involved in muscle re-
laxation. Previous studies have found conflicting results
in levels of phospholamben (Pln) expression in diabetes.
Pln is a key regulator of the sarcoplasmic reticulum
ATPase and thus involved in calcium handling [60]. An
increase in the mRNA and phospholamben protein
levels is postulated to cause an increase in sarcoplasmic
reticulum calcium reuptake inhibition [61]. In contrast
to the current study, Zhong et al. [62] found a 31-60%
increase in Pln in 4 and 6-week old streptozotocin-
induced type I diabetic rat heart [62]. There was one
Figure 1 Relationship between fold changes in gene expression measured by gene expression microarray and real-time PCR.
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streptozotocin-induced type I diabetic rat heart [63]. They
also measured the amount of Pln phosphorylation by
CaMK and PKA and found that to also be decreased and
therefore postulated that because Pln phosphorylation
inhibits the Pln inhibitory action, the decreased amount of
Pln was still able to cause impaired Ca uptake. Glycerol-
3-phosphate dehydrogenase (Gpd2) enhances lipid meta-
bolism by binding calcium. Expression of this protein was
decreased in streptozotocin-induced diabetic rat heart and
diaphragm, [12,14] similar to the current study. The last
decreased calcium binding gene in this group, S100 cal-
cium binding protein A3 (S100a3), has not changed in any
previous experiments with diabetes. The five increased
calcium genes (Myl6b, Casq2, Itga7, Cacnb2 and Sln) have
not had changed expression in previous diabetes studies.
Their functions involve calcium binding and calcium
channels. Sarcolipin (Sln) is also involved in sarcoplasmic
reticulum calcium regulation similar to phospholamben,
so it is possible that the increase in Sln expression could
be a compensatory mechanism for the decrease in Pln.
In the diabetic sternohyoid, three of the five calcium
channel genes with decreased expression (Fstl1, Atp2b3,
Eef2k, Gpd2, Myl6b) were decreased in previous diabetes
studies. Follistatin-like 1 (Fstl1) and glycerol-3-phosphate
dehydrogenase (Gpd2) were decreased in streptozotocin-
induced type 1 diabetic heart [14]. Atp2b3 protein content
was decreased in insulin-resistant Wistar rat islet plasma
membranes [64]. Several eukaryotic translation initiation
and elongation factors are decreased in streptozotocin-
induced diabetic rodent gastrocnemius muscle [8,65],
however until the present study eukaryotic elongation
factor kinase (Eef2k) has not previously been significantlychanged due to diabetes. Eef2k is completely dependent
on calcium and calmodulin and provides a key link be-
tween cellular energy status and the inhibition of pro-
tein synthesis [66-68]. Myl6b has not been significantly
changed in previous studies involving diabetes. Five cal-
cium genes were increased in the sternohyoid (Casq2,
S100a4, Mgl1, C1qb and C1qa). The S100a4 gene was
upregulated in a previous study in the peripheral leuko-
cytes of streptozotocin-induced diabetic rats [69], while
the other 4 did not have changed expression levels due
to diabetes.
There are several genes that were classified in the ion
channel GO grouping in the diaphragm that are involved
in other channels besides calcium ions. These genes are
Fxyd7, Scn3b and Kcnma1 which are involved in sodium
and potassium channels, Clcn4-2, which is a voltage-gated
chloride channel protein, Aqp1, which is a water channel,
and Slc30a4, which is a zinc transporter. Lrp1 is a trans-
membrane receptor which functions in the endocytosis of
over 40 structurally and functionally distinct ligands
[70,71]. Aquaporin 1 (Aqp1) is the only non-calcium
ion gene that has previously been examined in diabetes,
however with conflicting results. Baelde et al. [72] found
an increase in Aqp1 in human type II diabetic kidney,
while others found no changes in protein levels in
kidneys of streptozotocin-induced diabetic mice [73]
and streptozotocin-induced diabetic rats [74].
There are also several genes that were classified in the
ion channel GO grouping in the sternohyoid that are in-
volved in other ion channels besides calcium. These genes
are Fxyd2, Atp1b2 and Kcnma1 which are involved in so-
dium and potassium channels, Impa2 and Acsl6, which
are regulated by magnesium, Slc16a3, which transports
Table 5 Specific Gene Ontology groups and number of genes which were examined in more detail in type II diabetic
diaphragm and the corresponding changes in genes in type I diabetic diaphragm in a previous study (12)
GO group category & specific GO term Diaphragm Diaphragm
Type II Type I
# genes P value # genes P value
Metbolism - Lipid
Lipid metabolic process 9 0.019
Long-chain fatty acid transport 2 0.048
Cellular lipid metabolic process




Carbohydrate metabolic process 7 0.04 8 0.000061
Monosaccharide metabolic process 6 0.0037 5 0.0059
Hexose metabolic process 6 0.0036 5 0.0059
Cellular carbohydrate metabolic process 6 0.034 5 0.005






Contractile fiber part 4 0.01
Contractile fiber 4 0.014
Striated muscle contraction 3 0.014
Muscle system process
Muscle contraction
Regulation of muscle contraction
Ion transport
Ion transport 12 0.0015
Calcium ion binding 9 0.024 10 0.00003
Inorganic anion transport 5 0.0072
Anion transport 5 0.015
Regulation of ion transport 3 0.014
Channel activity 6 0.031
Magnesium ion binding
Collagen
Fibrillar collagen 3 0.0015 3 0.00033
Collagen 3 0.018 4 0.00014
Collagen type I 2 0.013
Blood circulation
Blood circulation 5 0.016
Circulatory system process 5 0.017
Oxidoreductase activity
Oxidoreductase activity 10 0.035 8 0.024
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Table 6 Genes with changed expression in diaphragm of type II and type I (12) diabetic rats that were assigned to
specific statistically over-represented gene ontology (GO) terms
TYPE II DIAPHRAGM
Gene Fold
Oxidoreductase activity Symbol Change
2,4-dienoyl CoA reductase 1, mitochondrial Decr1 2
IMP (inosine monophosphate) dehydrogenase 2 Impdh2 1.6
Potassium large conductance calcium-activated channel subfamily M, alpha member 1 Kcnma1 1.5
Solute carrier family 30 (zinc transporter), member 4 Slc30a4 1.5
Coenzyme Q7 homolog, ubiquinone (yeast) Coq7 −1.6
Glycerol-3-phosphate dehydrogenase 2, mitochondrial Gpd2 −1.7
S100 calcium binding protein A3 S100a3 −1.7
Dicarbonyl L-xylulose reductase Dcxr −2
Phytanoyl-CoA dioxygenase domain containing 1 Phyhd1 −2.1
Transmembrane 7 superfamily member 2 Tm7sf2 −2.5
Carbohydrate metabolism
protein kinase, AMP-activated, alpha 1 catalytic subunit Prkaa1 2.2
UDP-glucose pyrophosphorylase 2 Ugp2 −1.5
Solute carrier family 2 (facilitated glucose transporter), member 4 Slc2a4 −1.5
Coenzyme Q7 homolog, ubiquinone (yeast) Coq7 −1.6
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 Pfkfb1 −1.7
Glycerol-3-phosphate dehydrogenase 2, mitochondrial Gpd2 −1.7
Dicarbonyl L-xylulose reductase Dcxr −2
Collagen
Collagen, type I, alpha 2 Col1a2 −1.6
Collagen, type III, alpha 1 Col3a1 −1.7
Collagen, type I, alpha 1 Col1a1 −2
Ficolin (collagen/fibrinogen domain containing) 1 Fcn1 −2.1
TYPE I DIAPHRAGM
Oxidoreductase activity
Cytochrome P450, family 2, subfamily e, polypeptide 1 Cyp2e1 6
Flavin containing monooxygenase 3 Fmo3 2.9
Crystallin, lamda 1 Cryl1 2.4
Lysyl oxidase Lox 2.3
Ceruloplasmin Cp 2.2
2,4-dienoyl CoA reductase 1, mitochondrial Decr1 2.2
Aldehyde oxidase 1 Aox1 2.1
P450 (cytochrome) oxidoreductase Por 2.1
Carbohydrate metabolism
Neuraminidase 2 Neu2 −8.5
Phosphofructokinase, liver, B-type Pfkl −3.7
Solute carrier family 37 (glycerol-6-phosphate transporter), member 4 Slc37a4 −2.5
Glycerol-3-phosphate dehydrogenase 2 Gpd2 −2.3
Amylase 1, salivary Amy1 −2.3
Phosphoglycerate mutase 2 Pgam2 −2.1
Lactate dehydrogenase A Ldha −2
Phosphoglucomutase 1 Pgm1 −2
Dihydrolipoamide S-acetyltransferase Dlat −2
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Table 6 Genes with changed expression in diaphragm of type II and type I (12) diabetic rats that were assigned to
specific statistically over-represented gene ontology (GO) terms (Continued)
Collagen
Collagen, type III, alpha 1 Col3a1 −3.7
Collagen, type 1, alpha 1 Col1a1 −3.5
Procollagen, type I, alpha 2 Col1a2 −3.2
Fibrillin 1 Fbn1 −2.8
Secreted acidic cysteine rich glycoprotein Sparc −2.7
Collagen, type V, alpha 1 Col5a1 −2.4
Collagen, type V, alpha 3 Col5a3 −2.2
Fold changes in gene expression are represented in the last column. Genes in bold are common between type II and type I.
Figure 2 Genes with changed expression in diabetic diaphragm and diabetic sternohyoid muscle that are involved in specific steps of
fatty acid β-oxidation. Genes with increased expression in both muscles diaphragm are indicated in red; genes with decreased expression in
both muscles are indicated in green. Genes with increased expression in sternohyoid only are indicated in purple. Numbers indicate fold changes
in diaphragm/sternohyoid.
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Chrnd, which binds acetylcholine, and Ltbp1, which
binds TGF-B in order to regulate several collagens.
Similar to the present study, Fxyd2, a Na/K ATPase
regulator, has increased in human type II diabetic kid-
neys [72]. Changes in Atp1b2 and Kcnma1 expression
have not been found in previous studies. In the present
study, Impa2 increased and Acsl6 decreased. However
in previous studies, the expression of Impa2 was de-
creased in type 2 genetically-affected (OLETF) diabetic
cornea [75] and the expression of Acsl6 was decreased
in streptozotocin-induced diabetic rat diaphragm [12]
and heart [33]. The remaining non-calcium ion channel
genes in the sternohyoid, Slc16a3, Amy1a, Chrnd and
Ltbp1 did not have changed expression in previous
studies of diabetes.
Collagen
In the present study there were several collagen genes
which were decreased in type 2 diabetic diaphragm
(Col1a1, Col1a2, Col3a1) and sternohyoid (Col1a1,
Col1a2, Col5a1), similar to previous studies. In previous
studies, all of these collagen genes were significantly
decreased in streptozotocin-induced diabetic rat dia-
phragm with fold changes greater than 2.0 [12]. Col1a2,
Col3a1 and Col5a1expression were also decreased in
streptozotocin-induced diabetic rat heart [14]. Col1a1
had decreased expression in db/db type 2 diabetic mice
[76] and streptozotocin-induced diabetic rat gastrocne-
mius [8]. Col1a2 was decreased in newly forming bone
of streptozotocin-induced diabetic mice [77].
Blood circulation
In the blood circulation group that had significant
changes in only the diaphragm, there was only one gene
that was not also listed in another group and therefore
not mentioned yet. Apelin (Apln) plays a role in normal
glucolipidic metabolism [78] and has had conflicting re-
sults in previous experiments. The results of the present
study agree with the results previous results of low
plasma levels in type II diabetic Chinese humans
[79,80]. There have also been other reports of both
increased and decreased Apln levels in patients with
type 2 diabetes [79,81].
Oxidoreductase
In a previous study in streptozotocin-induced diabetic
rat diaphragm, we found an increased expression in
genes related to oxidative stress [12]. In the present
study, there were 3 genes that were not also listed in
another GO group (Decr1, Impdh2, Phyhd1). Decr1 ca-
talyzes the conversion of trans-2,3-didehydroacyl-CoA
and NADP(+) into trans,trans-2,3,4,5-tetradehydroacyl-
CoA and NADPH. Similar to the present study, wehave previously found an increase in expression in
streptozotocin-induced diabetic rat heart [14]. Others
have also found a 5-fold stimulation of activity in the
liver mitochondria of streptozotocin-induced diabetic
rats [38] and an increased expression in limb skeletal
muscle of Zucker diabetic fatty rats [11]. Impdh2 and
Phyhd1 have not had changed expression in previous
diabetic studies.
Immune & inflammatory, and response to stress &
wounding
Most of the genes in these categories had increased
expression in the diabetic sternohyoid, similar to a
previous study in streptozotocin-induced diabetic liver
[82]. However, these increases were completely absent
in the diabetic diaphragm in the present study as well
as type 1 diabetic diaphragm in our previous study12.
Some of the sternohyoid genes with increased expression
are depicted on the complement activation, classical path-
way (Figure 3). One of the genes involved in the pathway
is adipsin (Adn). Adipsin assembles with complement
factor B to enzymatically cleave complement factor C3
to C3a-des-arg/ASP (acylation stimulating protein),
which stimulates triglyceride production in adipose
tissue [83]. It is the one complement component that
has had changed expression due to diabetes in previous
studies. Adipsin has increased in streptozotocin-induced
diabetic mouse endothelium [83] and in streptozotocin-
induced diabetic rat adipose tissue [84]. The complement
factors (C1qb, C1qa, Cfh) are also involved in the comple-
ment activation classical pathway (Figure 3), but have not
changed expression levels due to diabetes in previous
studies. Cdkn1a is a cyclin-dependent kinase inhibitor
[82]. It regulates cell division by arresting the cell cycle
and is induced by oxidative stress [85,86]. Cdkn1a has
increased expression in cardiac and soleus muscle of
streptozotocin-induced diabetic rats [45] and liver of
streptozotocin-induced diabetic mice [82].
All of the immune and inflammatory genes in the
sternohyoid with increased expression are contained
in the stress and wounding group too. The three
genes with decreased expression (Dpp4, Mx1 and
Spon2) are not contained in the stress and wounding
group or any other of the significant GO groups in
this study. Dipeptidyl peptidase IV (Dpp4) is a serine
protease that exists on the surface of various types
of cells and in a soluble form in plasma [87]. Circu-
lating Dpp4 levels have been reported to be both in-
creased [88,89] and decreased [90,91] in type 2 diabetic
patients and increased in type I diabetic patients [88].
Dpp4 increases have been measured in many tissues of
streptozotocin-induced diabetic rats [92]. Mx1 and Spon2
have had altered gene expression due to diabetes in any
previous study.
Figure 3 Genes with changed expression in diabetic sternohyoid muscle that are involved in specific steps of the complement activation
pathway. Genes with increased expression in sternohyoid only are indicated in purple, with numbers indicating fold changes. There were no changes
in complement-related gene expression changes in the diaphragm.
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In conclusion, the current study shows that type 2 dia-
betes produces significant changes in gene expression of
the diaphragm and sternohyoid muscles, many of which
were not expected based on previous data on type 1
streptozotocin-induced diabetic diaphragm [12] as well
as on both types 1 and type 2 diabetes in other muscle
types [8-11,14,32,93]. The diaphragm had more gene
expression decreases in carbohydrate metabolism due
to diabetes than the sternohyoid, while the increases inlipid metabolism genes were similar in both muscles.
Thus there was a larger metabolic gene expression shift
in the diaphragm than the sternohyoid. However, for
several other processes there were more closely shared
magnitudes of gene expression changes (muscle contrac-
tion, ion transport, collagen). In addition, there were se-
veral gene expression changes in the diabetic sternohyoid
that were not present in the diaphragm (immune & in-
flammatory, response to stress & wounding) and vice
versa (oxidoreductase activity, blood circulation). The
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gets in common as well as individual targets for future
treatment strategies aimed at improving muscle function
in diabetes and obstructive sleep apnea.
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